Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192)
SSE SSE Primary Summary
688192 Chart
People also search for
Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Dizal (Jiangsu) Pharmaceutical Co., Ltd. ever had a stock split?
Dizal (Jiangsu) Pharmaceutical Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Dr. Zhang Xiaolin Ph.D. CEO | SSE Exchange | CNE1000055W8 ISIN |
| CN Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Dizal (Jiangsu) Pharmaceutical Co., Ltd. focuses on the discovery, development, and commercialization of innovative medicines targeting cancer and immunological diseases. With its establishment in 2017, the company has positioned itself as a key player in the pharmaceutical industry, dedicating its efforts to advancing medical research and development. Based in Shanghai, China, Dizal is engaged in several clinical trials aimed at addressing critical challenges in the treatment of hematological malignancies and solid tumors, as well as immunological diseases, spotlighting its commitment to improving patient outcomes through scientific innovation.
Products and Services
- JAUKPO
- DZD8586
- ZEGFROVY
- DZD1516
- DZD2269
Currently in Phase II clinical trials, JAUKPO is being developed for the treatment of hematological malignancy and immunological diseases. This indicates the company's strong focus on addressing complex conditions with significant unmet medical needs, showcasing its expertise in immunotherapy and cancer treatment.
This candidate is in Phase I clinical trials targeting hematological malignancy. DZD8586 represents Dizal's commitment to expanding its portfolio in the fight against cancer, particularly focusing on blood-related cancers where innovative treatments can significantly improve patient care and outcomes.
ZEGFROVY is in Phase II clinical trials for the treatment of solid tumors. The development of this drug reflects the company’s efforts in tackling the broad spectrum of solid tumors through new molecular targets and pathways, potentially offering new options for patients with difficult-to-treat cancers.
Also in Phase II clinical trials for the treatment of solid tumors, DZD1516 is part of Dizal’s strategic approach to solid tumor oncology. By advancing multiple candidates through trials, Dizal aims to address various pathways and mechanisms of action, underlining its comprehensive approach to cancer therapy.
In Phase I clinical trials for the treatment of solid tumors, DZD2269 continues to build on Dizal’s portfolio of innovative oncology therapies. With an emphasis on solid tumors, the company's research into DZD2269 could lead to breakthroughs in cancer treatment, contributing to the broader goal of tackling cancer's complexity with novel therapeutic options.
